Table of Contents
Orion used a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 to say that patients are staying on its prostate cancer drug Nubeqa (darolutamide) for longer than Orion first assumed, and that the drug is moving into earlier disease. President and chief executive officer Dr. Liisa Hurme PhD said the drug’s strength “really comes from the product qualities”.
Orion: a raised outlook
The Finnish company upgraded its 2026 outlook on October 20, to net sales of EUR 2,070–2,140 million and operating profit of EUR 730–790 million, saying royalty income had grown faster than expected. In the third quarter Orion reported Nubeqa net sales of EUR 279.9 million, including EUR 222.3 million of royalties from partner Bayer.
Longer treatment, earlier patients
Hurme said Nubeqa’s safety profile has supported patients staying on treatment longer than Orion estimated in its original business cases. “So we are moving all the time in the earlier population,” Hurme said.
At ESMO 2026, an interim analysis of the DASL-HiCaP trial showed that adding darolutamide to hormone therapy and radiotherapy cut the risk of metastasis or death by 58% compared with placebo in prostate cancer at high risk of recurrence, according to Orion. Hurme said the safety profile should give Nubeqa a good position in earlier disease.
DASL-HiCaP is investigator-initiated, and Orion has said it plans to use its opt-in right if and when Bayer files for approval. Hurme said Bayer is considering the regulatory pathway, which probably means discussions with the FDA, “and when all that is here, then it’s time for us to act.”
On generic competition in the androgen receptor inhibitor class, Hurme said new prostate cancer studies keep including these drugs, so the class “will have a long, long road. It will keep on living.”
Supply and tariffs
Orion has said a European and a US-based contract manufacturer will make part of the darolutamide active ingredient. “I think when you get there to be this big, you need to have several sites,” Hurme said.
A White House fact sheet puts the US tariff on patented drugs from the European Union at 15%. Hurme said Orion is waiting to see how US customs applies it: “Right now, we don’t know exactly where it will be, how much.”
Pipeline
On opevesostat, the prostate cancer drug partnered with MSD, Orion estimates the two Phase 3 trials reach primary completion in 2028. Hurme said, “I wouldn’t make any assumptions ahead of that data”. Hurme said the drug’s mechanism, blocking production of steroid hormones, should be able to work in the breast, ovarian and endometrial cancers in MSD’s Phase 2 basket study.
For ODM-212, Orion’s in-house TEAD inhibitor, Hurme said one rival is slightly ahead and one slightly behind, and that “we see a very mild and nice side effect profile”. Orion expects the Phase 2 TEADES readout in late 2027. In October Orion reported dosing the first patient with ODM-216, its first biologic to reach clinical testing, a bispecific antibody targeting PVRIG and PD-L1. Hurme said Orion had promised at least one new Phase 1 start this year and promised at least one more.
Branded products
Hurme said women’s health is the fastest-growing branded area, with Orion reporting 45.5% third-quarter growth driven by its Divina hormone replacement range, while respiratory products, led by Easyhaler, bring in the most money. From January 2027, Branded Products will include the hospital business. “I think it’s very meaningful,” Hurme said, pointing to biosimilars licensed for Europe.
Deals
At its 2025 capital markets day, Orion said EUR 1 billion of new debt and 10% new equity would enable about EUR 2 billion of total M&A capacity. Asked for a new number, Hurme said “let’s not speak to any figure”, but said royalty income leaves Orion well placed: “we’re looking for something to acquire.”
About Orion
Orion Pharma is a Nordic pharmaceutical company that develops, manufactures and markets human and veterinary medicines and active pharmaceutical ingredients. Its core research areas are oncology and pain. Orion reported net sales of EUR 1,890 million in 2025 and employs about 4,000 people.
Onyx has covered prostate cancer screening and Neopharmed Gentili at this year’s Jefferies conference.
Sources: Orion fireside chat, Jefferies Global Healthcare Conference, London, November 17, 2026; Orion outlook upgrade (October 20, 2026); Orion January–September 2026 interim report (October 28, 2026) and results webcast; Orion DASL-HiCaP release (October 24, 2026); Orion ODM-216 release (October 5, 2026); Orion executive team changes (October 26, 2026); Orion investor presentation; Orion Capital Markets Day 2025; White House fact sheet on pharmaceutical tariffs (April 2, 2026)
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments